PROTOCOL BASED ON HEPATITIS C VIRUS NUCLEIC ACID TESTING TO OPTIMIZE RENAL TRANSPLANT FROM SEROPOSITIVE DONORS TO SERONEGATIVE RECIPIENTS. AN EUROPEAN EXPERIENCE

作者
Antonio Franco,Francesc Moreso,Asunción Sancho,Núria Esforzado,Javier Paúl,Santiago Llorente,Francisco Manuel González Roncero,Marta Crespo,Auxiliadora Mazuecos,Eduardo Mellini,Luis Guirado
出处
期刊:Transplantation [Wolters Kluwer]
卷期号:104 (S3): S267-S267
标识
DOI:10.1097/01.tp.0000699840.73466.a8
摘要

The transmission of hepatitis C virus(HCV) has been widely reported. Based on two key points: HCV-antibodies (HCV-Ab) positive, HCV nucleic acid testing (HCV-NAT) negative donors do no universally transmit the infection and the availability of a treatment with Direct-Acting Antiviral Agents (DAA) to prevent the transmission, we designed a protocol based on the immediate identification of HCV-Ab-positive donor as viremic (HCV-NAT positive), with a high risk of transmission, or non-viremic (HCV-NAT negative) with a low risk of transmission, to start an early treatment with DAA if needed. This is a propective, observational, multicenter study. Donors: HCV-Ab positive donors, aged less than 70 years, except those admitted in the penitentiary system and/or with active addiction to parenteral drugs. Recipients:HCV-Ab negative recipients with no clinical history of liver disease and a signed informed consent. Test performed: An immediate HCV-NAT test (Xpert HCV VIral Load assay, Cepheid, CA, USA) to detect HCV-NAT and classify the donor as infective or non-infective. Action taken: Action taken 1 (recipent from HCV-NAT-positive donors): treatment with glecaprevir and pibrentasvir from 6 hours before trasplant until 8 weeks later. Action taken 2 (recipient from HCV-NAT-negative donors): No antiviral treatment. Regular monitoring of HCV-NAT to start DAA was planned. The median follow-up period was 14 months (p25-75:9-20), minumun 6 months. We included 53 recipients, 35 males and 18 females, aged 57.3 years (IC 95% 54.2-60.4) from 31 deceased donors,19 males and 12 females, aged 54.1 years (IC 95% 50.6-57.6), 15 were previous drugs users (48,3%). Donor genotypes were: 1a:4,1b:13,3:3,4:1 ND:10. A total of 10 donors were HCV-NAT positive and 21 negative(14 of them, 66,6%, previously treated). Nine grafts were excluded from the protocol, 4 trasplanted to HCV-Ab positive recipients and 5 discarded due to bad perfusion. Action taken 1 (HCV-NAT-positive donors): 17 recipients Action taken 2 (HCV-NAT-negative donors): 36 recipients None of our 36 recipents from HCV-NAT-negative donors showed HCV-NAT during a minimun follow-up of 6 months but 2 of 17 recipents from HCV-NAT-positive donors developed high viremias due to a delayed start of DDA and 4 low (<100), but all were negative at 1 week after transplant. Eigth of 36 recipents (22.2%) from non-infected donors and 13 of 17 (76.4%) from infected donors showed HCV seroconversion during the follow up period, but modification of liver enzymes was not registered. No adverse event associated with DAA was recorded. One recipient of an HCV-NAT-negative died due to acute necrotizing pancreatitis after trasplantatiton and other had no primary function. The remaining 51 patients had a stable functioning graft at the end of the follow-up period, CKD-EPI between 35 and 65 ml/min. Conclusion: This data suggest that our protocol based on HCV-NAT testing to optimize the use of DAA in renal transplant from seropositive donors to seronegative recipients is safe.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
呼呼夫人完成签到,获得积分10
刚刚
2秒前
3秒前
3秒前
weitao0916完成签到,获得积分10
3秒前
冬冬完成签到,获得积分10
4秒前
小蘑菇的应助被杨淼采纳,获得10
4秒前
爱听歌的沛儿完成签到 ,获得积分20
4秒前
4秒前
5秒前
6秒前
李健的小迷弟的应助被晓天采纳,获得10
6秒前
张伟的应助被钱罐罐采纳,获得10
6秒前
Zzha10发布了新的文献求助10
6秒前
6秒前
是我呀吼发布了新的文献求助20
7秒前
Orange的应助被土豪的城采纳,获得30
9秒前
XS_QI发布了新的文献求助10
9秒前
还有早安完成签到,获得积分10
9秒前
安详的夜春完成签到,获得积分10
9秒前
小鱼干完成签到,获得积分10
9秒前
自由的王发布了新的文献求助10
10秒前
开朗紫发布了新的文献求助10
10秒前
叶95完成签到,获得积分10
11秒前
11秒前
12秒前
12秒前
Maestro_S的应助被小鱼干采纳,获得10
13秒前
13秒前
吕锴岐完成签到 ,获得积分10
14秒前
huang完成签到 ,获得积分10
14秒前
14秒前
zjjcug完成签到,获得积分10
14秒前
苦昼短完成签到 ,获得积分10
14秒前
zzl完成签到,获得积分10
14秒前
大个的应助被小青采纳,获得10
15秒前
anqi6688完成签到,获得积分10
15秒前
Zzha10完成签到,获得积分10
15秒前
CarryLJR发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568